Pfizer has reported its first-quarter 2026 earnings, exceeding market expectations with $14.5 billion in revenue. The company reaffirmed its full-year guidance, bolstered by a 22% operational growth in launched and acquired products.
Amgen has reported a robust start to the year, with its Q1 2026 financial results exceeding analyst estimates. Total revenue climbed to $8.6 billion, driven by double-digit growth across 16 key brands and a promising expansion of the MariTide obesity program.
Eli Lilly and Company’s Q1 2026 results showcased a 56% revenue surge to $19.8 billion, driven by unparalleled demand for its incretin portfolio and breakthrough oncology treatments.
Biogen reported a solid start to the year with its Q1 2026 results, featuring 12% growth in new products and a major move to acquire Apellis Pharmaceuticals to bolster its rare disease and nephrology portfolios.
AbbVie announced its first-quarter 2026 financial results, surpassing expectations with $15 billion in revenue and raising its full-year EPS guidance as next-generation immunology assets continue to offset Humira’s erosion.
AstraZeneca reports a robust start to 2026 with $15.3 billion in total revenue, driven by its powerhouse oncology and rare disease portfolios, alongside key clinical successes in COPD and hypophosphatasia.
Gilead Sciences has finalized its $7.8 billion acquisition of Arcellx, Inc., positioning the company for the potential 2026 commercial launch of the BCMA-directed CAR T-cell therapy, anito-cel.
Novartis reports a resilient Q1 2026 with major gains in oncology and immunology, despite expected generic competition in the US market.
Eli Lilly and Company expands its oncology portfolio through the Lilly Ajax Therapeutics acquisition, targeting breakthroughs in myeloproliferative neoplasms with AJ1-11095.
Sun Pharmaceutical Industries has announced a definitive agreement to acquire Organon & Co. for $11.75 billion, marking a major expansion into women’s health and biosimilars.
